Fig. 2.

Percent genome coverage at a depth of coverage of 20x for dengue virus stocks and clinical specimens. A/C/E/G) Initial validation of the serotype-specific approach was validated by sequencing virus stocks representing the majority of genotypes within each of the four serotypes. Dengue virus 2 genotype VI and dengue virus 4 genotype IV comprise sylvatic viruses, which were the only genotypes for which genome coverage was consistently below 100%. B/D/F/H) Additional sequencing was done from clinical specimens of patients diagnosed with dengue. Specimens comprised a wider range of RNA titers, and lower genome coverage with lower RNA copies. Phylogenetic trees showing the genome sequences used for validation are shown in Fig. S3 (virus stocks) and Fig. S4 (clinical specimens)